[
  {
    "ts": null,
    "headline": "Compass’s Psychedelic Drug to Treat Depression Meets Goal in Trial",
    "summary": "(Bloomberg) -- Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a late-stage trial.Most Read from BloombergBezos Wedding Draws Protests, Soul-Searching Over Tourism in VeniceOne Architect’s Quest to Save Mumbai’s Heritage From DisappearingNYC Congestion Toll Cuts Manhattan Gridlock by 25%, RPA ReportsThe company said its psilocybin drug reduced depression symptoms by 3.6 points on a rating scale compared to a placebo, meet",
    "url": "https://finnhub.io/api/news?id=008d12e2bc2a23b4542f3f9707e07b525d075b4874a22a4c0e2b3342a2148f69",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750686712,
      "headline": "Compass’s Psychedelic Drug to Treat Depression Meets Goal in Trial",
      "id": 135481689,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a late-stage trial.Most Read from BloombergBezos Wedding Draws Protests, Soul-Searching Over Tourism in VeniceOne Architect’s Quest to Save Mumbai’s Heritage From DisappearingNYC Congestion Toll Cuts Manhattan Gridlock by 25%, RPA ReportsThe company said its psilocybin drug reduced depression symptoms by 3.6 points on a rating scale compared to a placebo, meet",
      "url": "https://finnhub.io/api/news?id=008d12e2bc2a23b4542f3f9707e07b525d075b4874a22a4c0e2b3342a2148f69"
    }
  },
  {
    "ts": null,
    "headline": "Are You a Value Investor? This 1 Stock Could Be the Perfect Pick",
    "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
    "url": "https://finnhub.io/api/news?id=dd432191d18d57a5bb987b50e39b7a2ab1ae0e0f6def39e65477ca184aaa5f29",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750686003,
      "headline": "Are You a Value Investor? This 1 Stock Could Be the Perfect Pick",
      "id": 135481690,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
      "url": "https://finnhub.io/api/news?id=dd432191d18d57a5bb987b50e39b7a2ab1ae0e0f6def39e65477ca184aaa5f29"
    }
  },
  {
    "ts": null,
    "headline": "J&J Adds More Than $15B in Six Months: How to Play JNJ Stock?",
    "summary": "JNJ stock added $15B in market value in six months as new drug launches offset MedTech and Stelara headwinds.",
    "url": "https://finnhub.io/api/news?id=7ed278cf006eb3e3a9dbfc23c4678d28e3d998b349c14b34995012709b919acc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750684920,
      "headline": "J&J Adds More Than $15B in Six Months: How to Play JNJ Stock?",
      "id": 135481691,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "JNJ stock added $15B in market value in six months as new drug launches offset MedTech and Stelara headwinds.",
      "url": "https://finnhub.io/api/news?id=7ed278cf006eb3e3a9dbfc23c4678d28e3d998b349c14b34995012709b919acc"
    }
  },
  {
    "ts": null,
    "headline": "J&J's Drugs Get CHMP Recommendations for Blood Cancer Indications",
    "summary": "JNJ wins CHMP backing for Darzalex and Imbruvica in new blood cancer uses, paving the way for first-in-class approvals.",
    "url": "https://finnhub.io/api/news?id=deb522c5d398a4d0bf4062e39cf09ebf73620c590ff5e87bad6635d38a3478e0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750684500,
      "headline": "J&J's Drugs Get CHMP Recommendations for Blood Cancer Indications",
      "id": 135481692,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "JNJ wins CHMP backing for Darzalex and Imbruvica in new blood cancer uses, paving the way for first-in-class approvals.",
      "url": "https://finnhub.io/api/news?id=deb522c5d398a4d0bf4062e39cf09ebf73620c590ff5e87bad6635d38a3478e0"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Launches First and Only Daily Disposable Multifocal Toric Contact Lens - ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM",
    "summary": "Today, Johnson & Johnson,† a global leader in eye health, announced the launch of ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM, the first and only daily disposable contact lens for people with both astigmatism and presbyopia.2 This pioneering contact lens provides patients crisp, clear, stable vision at all distances and in all lighting conditions, along with comfort that lasts all day.1 The lens is now available in the U.S. and Canada, and the launch of ACUVUE OASYS MAX 1-Day for ASTIGMATI",
    "url": "https://finnhub.io/api/news?id=b690a656854393314fafcfb30c0b30560cc77821b3a0f9685808c3e10987afa7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750680000,
      "headline": "Johnson & Johnson Launches First and Only Daily Disposable Multifocal Toric Contact Lens - ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM",
      "id": 135481693,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Today, Johnson & Johnson,† a global leader in eye health, announced the launch of ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM, the first and only daily disposable contact lens for people with both astigmatism and presbyopia.2 This pioneering contact lens provides patients crisp, clear, stable vision at all distances and in all lighting conditions, along with comfort that lasts all day.1 The lens is now available in the U.S. and Canada, and the launch of ACUVUE OASYS MAX 1-Day for ASTIGMATI",
      "url": "https://finnhub.io/api/news?id=b690a656854393314fafcfb30c0b30560cc77821b3a0f9685808c3e10987afa7"
    }
  },
  {
    "ts": null,
    "headline": "IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced new data from an indirect treatment comparison (ITC) that showed consistent and sustained disease control with IMAAVY™ (nipocalimab-aahu) versus other approved FcRn blockers in adults with generalized myasthenia gravis (gMG). These data, featured at the European Academy of Neurology (EAN) 2025 Congress in Helsinki, Finland, are among the 11 abstracts Johnson & Johnson is presenting.",
    "url": "https://finnhub.io/api/news?id=b223372e7c99c9656e3b196519ddca18c1de2b2c4b7f33480a91462107251cd5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750678320,
      "headline": "IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)",
      "id": 135481695,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced new data from an indirect treatment comparison (ITC) that showed consistent and sustained disease control with IMAAVY™ (nipocalimab-aahu) versus other approved FcRn blockers in adults with generalized myasthenia gravis (gMG). These data, featured at the European Academy of Neurology (EAN) 2025 Congress in Helsinki, Finland, are among the 11 abstracts Johnson & Johnson is presenting.",
      "url": "https://finnhub.io/api/news?id=b223372e7c99c9656e3b196519ddca18c1de2b2c4b7f33480a91462107251cd5"
    }
  },
  {
    "ts": null,
    "headline": "J&J: favorable data in severe myasthenia gravis",
    "summary": "Johnson & Johnson announced on Monday that Imaavy has demonstrated better disease control in patients with generalized myasthenia gravis .These data, presented at the 2025 Congress of the European...",
    "url": "https://finnhub.io/api/news?id=751ebbf276fdaa5bd56987f3e2bdc3a811045a8cc37cbac635abe193efd1a4d4",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750674036,
      "headline": "J&J: favorable data in severe myasthenia gravis",
      "id": 135477379,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson announced on Monday that Imaavy has demonstrated better disease control in patients with generalized myasthenia gravis .These data, presented at the 2025 Congress of the European...",
      "url": "https://finnhub.io/api/news?id=751ebbf276fdaa5bd56987f3e2bdc3a811045a8cc37cbac635abe193efd1a4d4"
    }
  },
  {
    "ts": null,
    "headline": "Zacks Investment Ideas feature highlights: Jabil, Apple, Amazon, Johnson & Johnson and Ericsson",
    "summary": "Jabil tops Q3 estimates with 35% EPS growth, strong guidance, and momentum from key clients like Apple and Amazon.",
    "url": "https://finnhub.io/api/news?id=107790d729422fa3ff3d6504ce8af82f42722b41e8f983e855ba1c23dd60b3fe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750669500,
      "headline": "Zacks Investment Ideas feature highlights: Jabil, Apple, Amazon, Johnson & Johnson and Ericsson",
      "id": 135481593,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Jabil tops Q3 estimates with 35% EPS growth, strong guidance, and momentum from key clients like Apple and Amazon.",
      "url": "https://finnhub.io/api/news?id=107790d729422fa3ff3d6504ce8af82f42722b41e8f983e855ba1c23dd60b3fe"
    }
  },
  {
    "ts": null,
    "headline": "Compass shares hits record low after depression drug fails to impress",
    "summary": "Compass Pathways'psilocybin-based depression therapy reduced the severity ofsymptoms in a closely watched study, but shares of the biotechfirm plunged more than 46% to a record low on Monday as...",
    "url": "https://finnhub.io/api/news?id=b01ae61facf4e75274dc3b1c9f6a19726e6a60f1972c092c1bf8fd0946e51d4b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750662077,
      "headline": "Compass shares hits record low after depression drug fails to impress",
      "id": 135482083,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Compass Pathways'psilocybin-based depression therapy reduced the severity ofsymptoms in a closely watched study, but shares of the biotechfirm plunged more than 46% to a record low on Monday as...",
      "url": "https://finnhub.io/api/news?id=b01ae61facf4e75274dc3b1c9f6a19726e6a60f1972c092c1bf8fd0946e51d4b"
    }
  }
]